Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder
Brain Research · 2023
DOI: 10.1016/j.brainres.2023.148443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2023. Verfasst von Arushi Sandhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER), 4th Floor, Research Block B, Chandigarh 160012, India. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Phosphodiesterase Inhibitors, Prenatal Exposure Delayed Effects, Valproic Acid. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Post Graduate Institute of Medical Education and Research.
Abstract (Originalsprache)
BACKGROUND: Autism spectrum disorder (ASD) is categorized as a neurodevelopmental disorder, presenting with a variety of aetiological and phenotypical features. Ibudilast is known to produce beneficial effects in several neurological disorders including neuropathic pain, multiple sclerosis, etc. by displaying its neuroprotective and anti-inflammatory properties. Here, in our study, the pharmacological outcome of ibudilast administration was investigated in the prenatal valproic acid (VPA)-model of ASD in Wistar rats. METHODS: Autistic-like symptoms were induced in Wistar male pups of dams administered with Valproic acid (VPA) on embryonic day 12.5. VPA-exposed male pups were administered with two doses of ibudilast (5 and10 mg/kg) and all the groups were evaluated for behavioral parameters like social interaction, spatial memory/learning, anxiety, locomotor activity, and nociceptive threshold. Further, the possible neuroprotective effect of ibudilast was evaluated by assessing oxidative stress, neuroinflammation (IL-1β, TNF-α, IL-6, IL-10) in the hippocampus, % area of Glial fibrillary acidic protein (GFAP)-positive cells and neuronal damage in the cerebellum. KEY FINDINGS: Treatment with ibudilast significantly attenuated prenatal VPA exposure associated social interaction and spatial learning/memory deficits, anxiety, hyperactivity, and increased nociceptive threshold, and it decreased oxidative stress markers, pro-inflammatory markers (IL-1β, TNF-α, IL-6), and % area of GFAP-positive cells and restored neuronal damage. CONCLUSIONS: Ibudilast treatment has restored crucial ASD-related behavioural abnormalities, potentially through neuroprotection. Therefore, benefits of ibudilast administration in animal models of ASD suggest that ibudilast may have therapeutic potential in the treatment of ASD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER), 4th Floor, Research Block B, Chandigarh 160012, India.
- Department of Pharmacology, Post Graduate Institute of Medical Education & Research (PGIMER), 4th Floor, Research Block B, Chandigarh 160012, India. Electronic address: saha.lekha@pgimer.edu.in.
Förderung
- Post Graduate Institute of Medical Education and Research
Zitieren
APA
Sandhu, A., Rawat, K., Gautam, V., Sharma, A., Kumar, A., & Saha, L. (2023). Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Brain Research. https://doi.org/10.1016/j.brainres.2023.148443
Vancouver
Sandhu A, Rawat K, Gautam V, Sharma A, Kumar A, Saha L. Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder. Brain Research. 2023. doi:10.1016/j.brainres.2023.148443
BibTeX
@article{Sandhu2023,
author = {Sandhu, Arushi and Rawat, Kajal and Gautam, Vipasha and Sharma, Antika and Kumar, Anil and Saha, Lekha},
title = {Phosphodiesterase inhibitor, ibudilast alleviates core behavioral and biochemical deficits in the prenatal valproic acid exposure model of autism spectrum disorder},
journal = {Brain Research},
year = {2023},
doi = {10.1016/j.brainres.2023.148443}
}
EUVIMED